DUXAP10 gene

Known as: DUXAP10, double homeobox A pseudogene 10 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Highly expressed long non-coding RNA DUXAP10 promotes proliferation of ovarian cancer.
OBJECTIVE To investigate the expression of long non-coding RNA DUXAP10 in ovarian cancer and its effect on ovarian cancer cell… (More)
Is this relevant?
2018
2018
DUXAP10 regulates proliferation and apoptosis of chronic myeloid leukemia via PTEN pathway.
OBJECTIVE To investigate the role of DUXAP10 in chronic myelogenous leukemia (CML) and its underlying mechanism. PATIENTS AND… (More)
Is this relevant?
2018
2018
Over-expression of oncigenic pesudogene DUXAP10 promotes cell proliferation and invasion by regulating LATS1 and β-catenin in gastric cancer
BACKGROUND Recently, the pesudogenes have emerged as critical regulators in human cancers tumorigenesis and progression, and been… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
The pseudogene derived from long non-coding RNA DUXAP10 promotes colorectal cancer cell growth through epigenetically silencing of p21 and PTEN
Recently, substantial evidence has demonstrated that pseudogene derived lncRNAs are crucial regulators of cancer development and… (More)
Is this relevant?
2017
2017
The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer
Pseudogenes have been considered as non-functional transcriptional relics of human genomic for long time. However, recent studies… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2017
2017
Knockdown of DUXAP10 inhibits proliferation and promotes apoptosis in bladder cancer cells via PI3K/Akt/mTOR signaling pathway.
DUXAP10 is a member of long non-coding RNAs (lncRNAs) and has been reported to be upregulated in bladder cancer (BC) tissues… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?